ASSFN Position Statement on Deep Brain Stimulation for Medication-Refractory Epilepsy.
Publication/Presentation Date
5-1-2022
Abstract
Neuromodulation has taken a foothold in the landscape of surgical treatment for medically refractory epilepsies and offers additional surgical treatment options for patients who are not candidates for resective/ablative surgery. Approximately one third of patients with epilepsy suffer with medication-refractory epilepsy. A persistent underuse of epilepsy surgery exists. Neuromodulation treatments including deep brain stimulation (DBS) expand the surgical options for patients with epilepsy and provide options for patients who are not candidates for resective surgery. DBS of the bilateral anterior nucleus of the thalamus is an Food and Drug Administration-approved, safe, and efficacious treatment option for patients with refractory focal epilepsy. The purpose of this consensus position statement is to summarize evidence, provide recommendations, and identify indications and populations for future investigation in DBS for epilepsy. The recommendations of the American Society of Functional and Stereotactic Neurosurgeons are based on several randomized and blinded clinical trials with high-quality data to support the use of DBS to the anterior nucleus of the thalamus for the treatment of refractory focal-onset seizures.
Volume
90
Issue
5
First Page
636
Last Page
641
ISSN
1524-4040
Published In/Presented At
Gummadavelli, A., Englot, D. J., Schwalb, J. M., Wu, C., Gonzalez-Martinez, J., Niemat, J., Gerrard, J. L., & American Society for Stereotactic and Functional Neurosurgeons (2022). ASSFN Position Statement on Deep Brain Stimulation for Medication-Refractory Epilepsy. Neurosurgery, 90(5), 636–641. https://doi.org/10.1227/neu.0000000000001923
Disciplines
Medicine and Health Sciences
PubMedID
35271523
Department(s)
Department of Surgery
Document Type
Article
